ITC to Investigate Amgen Complaint Over Roche’s Anemia Drug

Drug Industry Daily
KEYWORDS Markets / Patents
A A

The U.S. International Trade Commission (ITC) plans to investigate Amgen’s claim that Roche’s importation of the anemia drug Cera violates Amgen’s patents on its anemia treatment Epogen, Amgen said May 9.

To View This Article:

Login

Subscribe To Drug Industry Daily